Latest news with #RHI
Business Standard
20-05-2025
- Business
- Business Standard
Eris Lifesciences gains after Q4 PAT climbs 32% YoY to Rs 94 cr
Eris Lifesciences added 1.22% to Rs 1,461 after the company's consolidated net profit jumped 32.1% to Rs 93.84 crore on 28.4% increase in revenue from operations to Rs 702.60 crore in Q4 FY25 over Q4 FY24. Profit before tax (PBT) climbed 67.9% YoY to Rs 128.87 crore in Q4 FY25. During the quarter EBITDA stood at Rs 252 crore, up 70% compared with Rs 148 crore posted in same quarter last year. EBITDA margin expanded to 35.8% in Q4 FY25 as against 26.9% in Q4 FY24. Revenue from domestic branded formulation (DBF) business jumped 25% YoY to Rs 602 crore in Q4 FY25. The organic base grew 10% to Rs 529 crore, while revenue from Biocon -2 stood at Rs 73 crore during the period under review. The company reported 22% organic growth in overall insulin revenue to Rs 300 crore despite significant product shortage in RHI throughout the year. On full year basis, the companys consolidated net profit declined 10.3% to Rs 351.84 crore on 44.6% increase in revenue from operations to Rs 2,879.26 crore in FY25 over FY24. On guidance front, for FY26, the company projects an annual revenue addition of Rs 200300 crore to its overall insulin franchise, beginning October 2025, driven by the insourcing of insulin production at its Bhopal facility. This strategic move is expected to significantly enhance its insulin portfolio. In DBF business, the company anticipates revenue growth of 15% to 21%, translating to revenues in the range of Rs 2,9003,050 crore. EBITDA for the segment is projected between Rs 1,070 crore and Rs 1,130 crore, with EBITDA margins maintained around 37%. Additionally, the company expects revenues from its Swiss Parentals division to range between Rs 375- 390 crore reflecting a growth of 1520%. EBITDA for this segment is estimated between Rs 130 crore and Rs 135 crore, with an EBITDA margin of approximately 35%. The company plans to expand Eris-AMD, its new injectable facility, with a capital expenditure of Rs 100- 200 crore in FY26. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.
Malaysian Reserve
18-05-2025
- Business
- Malaysian Reserve
RKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rock Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, May 18, 2025 /PRNewswire/ — Attorney Advertising– Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rock Holdings, Inc. ('RHI' or 'the Company') (NYSE: RKT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Rocket Companies, Inc. ('Rocket') Class A common stock between February 25, 2021 and May 5, 2021, both dates inclusive (the 'Class Period'). Such investors are encouraged to join this case by visiting the firm's site: Case Details The Complaint alleges that while in possession of material, non-public, adverse information, Defendant RHI on March 29, 2021, sold 20,200,000 shares of Rocket Class A common stock at $24.75 per unit, for total proceeds of $499.95 million. The Complaint adds that class members purchased Rocket stock contemporaneously with the Defendants' sale of stock without access to this material, non-public, adverse information, and suffered damages. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in RHI you have until July 8, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. ContactBronstein, Gewirtz & Grossman, LLCPeretz Bronstein or Nathan Miller332-239-2660 | info@
Business Wire
09-05-2025
- Business
- Business Wire
Labaton Keller Sucharow LLP Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Rock Holdings, Inc.
NEW YORK--(BUSINESS WIRE)--Labaton Keller Sucharow LLP ('Labaton') announces the reopening of the lead plaintiff appointment process in a class action lawsuit against Rock Holdings, Inc. ('RHI'). The action, which is captioned Construction Laborers Pension Trust for Southern California v. Rocket Companies, Inc., No. 21-cv-11528-TLL-APP (E.D. Mich.) asserts claims under Section 10(b) and Section 20A of the Securities Exchange Act of 1934, on behalf of all persons who purchased Rocket Companies, Inc. ('Rocket') Class A common stock on March 29, 2021 through April 1, 2021, inclusive. The action alleges that while in possession of material, non-public, adverse information, Defendant RHI on March 29, 2021, sold 20,200,000 shares of Rocket Class A common stock at $24.75 a unit, for total proceeds of $499.95 million. Plaintiff Construction Laborers Pension Trust for Southern California ('SoCal') and members of the Class purchased Rocket stock contemporaneously with Defendant RHI's sale of stock without access to this material, non-public, adverse information. On April 17, 2025, the Court issued an Opinion and Order in which it granted Plaintiff SoCal's motion for leave to file a renewed motion for class certification. In addition, the Court ordered that, to the extent Plaintiff SoCal wished to seek renewed class certification on narrowed insider trading claims, it was directed to publish this notice. If you purchased or acquired Rocket Class A common stock on March 29, 2021 through April 1, 2021 and were damaged thereby, you may be a member of the 'Class' and may be able to seek appointment as Lead Plaintiff. Lead Plaintiff motion papers must be filed no later than July 8, 2025. The Lead Plaintiff is a court-appointed representative for absent members of the Class. You do not need to seek appointment as Lead Plaintiff to share in any Class recovery in this action. If you are a Class member and there is a recovery for the Class, you can share in that recovery as an absent Class member. You may retain counsel of your choice to represent you in this action including in making a motion for appointment as Lead Plaintiff. If you would like to consider serving as Lead Plaintiff or have any questions about this lawsuit, you may contact Connor C. Boehme, Esq. of Labaton at (212) 907-0780, or via email at cboehme@ Plaintiff SoCal is represented by Labaton, which represents many of the largest pension funds in the United States and internationally with combined assets under management of more than $4.5 trillion. Labaton's litigation reputation is built on its half-century of securities litigation experience, more than ninety full-time attorneys, and in-house team of investigators, financial analysts, and forensic accountants. Labaton has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, Delaware, London, and Washington, D.C. More information about Labaton is available at
San Francisco Chronicle
23-04-2025
- Business
- San Francisco Chronicle
Robert Half: Q1 Earnings Snapshot
MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Robert Half International Inc. (RHI) on Wednesday reported first-quarter net income of $17.4 million. The Menlo Park, California-based company said it had net income of 17 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 36 cents per share. The staffing firm posted revenue of $1.35 billion in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $1.4 billion.
Yahoo
23-04-2025
- Business
- Yahoo
Is Robert Half Inc. (RHI) The Top Falling Stock with Unusual Volume?
We recently published a list of . In this article, we are going to take a look at where Robert Half Inc. (NYSE:RHI) stands against other top falling stocks with unusual volume. Uncertainty around tariffs and macroeconomic conditions has dented investor confidence, resulting in stock prices falling. While some stocks have come under pressure due to the above two reasons, others have simply followed the market direction or have dipped for company-specific reasons. Regardless of the reasons for stocks going down, falling stocks provide an opportunity for fresh investors to get in at good prices. Once the risks subside, these stocks usually recover quickly as well. We decided to uncover these stocks and see if it makes sense to put money in them to take advantage of the ongoing market turmoil. To come up with our list of top 20 stocks falling with unusual volume, we looked at stocks over $300 million in market cap, their one-week performance, and used relative volume to detect the unusual volume activity. Relative volume compares the daily volume to the three-month average trading volume of the stock, making it easy to detect spikes in volume. These spikes usually signal something important is happening, which, when combined with falling prices, becomes a red flag that investors can't ignore. A finance executive in her office analyzing a stack of documents. Robert Half Inc. operates as a talent solutions and business consulting services provider. It operates in Contract Talent Solutions, Protiviti, and Permanent Placement Talent Solutions segments. The stock is down 6.35% in a week on a relative volume of 2.01. The stock is struggling leading up to the Q2 earnings. The company predicted an 8% to 10% YoY growth. While a decline in margins in the first quarter is the norm, all eyes will be on the size of the decline. Back in January, there was still optimism that Donald Trump would spur rate cuts. RHI management boasted about the strength of the small businesses to point towards a good 2025. All that optimism has evaporated now as small businesses are the most likely to suffer in the case of a recession. The stock's 37% YTD decline, the majority of which came after the earnings report in January, is raising question marks over the company's prospects as well as its ability to maintain a high dividend yield. Overall, RHI ranks 15th on our list of top falling stocks with unusual volume. While we acknowledge the potential of RHI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than RHI but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Sign in to access your portfolio
